Evaluation of Plasma Concentration and Hepatotoxicity of Voriconazole in Pediatric Patients following Hematopoietic Stem Cell Transplantation
Abstract
Background: Invasive fungal infection is one of the most important causes of morbidity and mortality in pediatric patients undergoing Hematopoietic stem cell transplantation (HSCT). Voriconazole as a broad-spectrum anti-fungal agent which has been used widely for prevention and treatment of invasive fungal infections in immunocompromised patients. Alteration in voriconazole plasma concentrations may be resulted in lack of efficacy and some adverse effects.
Methods: This observational cohort study assessed the therapeutic plasma concentration of voriconazole and its relationship with hepatotoxic adverse effect in pediatric patients undergoing HSCT. Plasma concentration of voriconazole was measured by High-performance liquid chromatography (HPLC) assay with technique extracted from Khoschsorur et al.
Results: Among a total of 14 pediatric patients,5 patients received voriconazole orally and 9 patients received voriconazole intravenously. The median plasma concentration of voriconazole was 1.8 mcg/ml (range, 0.75-5.54 mcg/ml). There was no correlation between voriconazole dose and plasma concentration of voriconazole(p=0.166). Trough concentration of ≥ 4 mcg/ml was observed in 2 of 3 patients who experienced severe hepatic dysfunction. The plasma concentration of voriconazole did not significantly differ in patients with or without hepatotoxicity(p=0.406).
Conclusions: Our study showed that trough levels of voriconazole were sub-therapeutic in 21.4% of children. Furthermore, hepatic enzyme abnormalities were observed in half of pediatric patients following voriconazole initiation during hospitalization. We didn’t find any correlation between plasma concentration of voriconazole and the incidence of hepatotoxicity. We also didn’t observe any correlation between voriconazole dose and plasma concentration of voriconazole, but the correlation was linear after exclusion of outlier data.
Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010;26(7):1779-87.
Hope WW, Walsh TJ, Goodwin J, et al. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. J AntimicrobChemother 2016;71(8):2234-40
Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamicprofile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63.
Rathbun RC, Hoffman HL. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11(3):409-29.
Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 2013;60(1):82-7.
Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob agents chemother 2010 ;54(10):4116-23.
Khoschsorur G, Fruehwirth F, Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metaboliteinhumanserum.Antimicrobagentschemother2005;49(8):3569-71.
Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA.Voriconazole monitoring in children with invasive fungal infections. JPediatr Pharmacol Ther 2015;20(1):17-23.
Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis2010;50(1):27-36.
Soler-Palacín P, Frick MA, Martín-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2011; 67(3): 700-6.
Gerin M, Mahlaoui N, Elie C, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monitor 2011;33(4):464-6.
Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004;48(6):2166-72.
Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012;12(7):1929-35.
Kim BK, Chung KW, Sun HS, et al. Liver disease during the first post- transplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplant 2000;26(2):193-7.
| Files | ||
| Issue | Vol 4, No 1-2 (Spring 2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| voriconazole pediatric hepatotoxicity HSCT | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
